TY - JOUR
T1 - Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis
T2 - A multicenter cross-sectional study
AU - Hamaguchi, Yasuhito
AU - Kuwana, Masataka
AU - Hoshino, Kana
AU - Hasegawa, Minoru
AU - Kaji, Kenzo
AU - Matsushita, Takashi
AU - Komura, Kazuhiro
AU - Nakamura, Motonobu
AU - Kodera, Masanari
AU - Suga, Norihiro
AU - Higashi, Akira
AU - Ogusu, Koji
AU - Tsutsui, Kiyohiro
AU - Furusaki, Akira
AU - Tanabe, Hiroshi
AU - Sasaoka, Shunsuke
AU - Muro, Yoshinao
AU - Yoshikawa, Mika
AU - Ishiguro, Naoko
AU - Ayano, Masahiro
AU - Muroi, Eiji
AU - Fujikawa, Keita
AU - Umeda, Yukihiro
AU - Kawase, Masaaki
AU - Mabuchi, Eriko
AU - Asano, Yoshihide
AU - Sodemoto, Kinuyo
AU - Seishima, Mariko
AU - Yamada, Hidehiro
AU - Sato, Shinichi
AU - Takehara, Kazuhiko
AU - Fujimoto, Manabu
PY - 2011/4
Y1 - 2011/4
N2 - Objective: To clarify the association of clinical and prognostic features with dermatomyositis (DM)-specific autoantibodies (Abs) in adult Japanese patients with DM. Design: Retrospective study. Setting: Kanazawa University Graduate School of Medical Science Department of Dermatology and collaborating medical centers. Patients: A total of 376 consecutive adult Japanese patients with DM who visited our hospital or collaborating medical centers between 2003 and 2008. Main Outcome Measures: Clinical and laboratory characteristics of adult Japanese patients with DM and DMspecific Abs that include Abs against Mi-2, 155/140, and CADM-140. Results: In patients with DM, anti-Mi-2, anti-155/140, and anti-CADM-140 were detected in 9 (2%), 25 (7%), and 43 (11%), respectively. These DM-specific Abs were mutually exclusive and were detected in none of 34 patients with polymyositis, 326 with systemic sclerosis, and 97 with systemic lupus erythematosus. Anti-Mi-2 was associated with classical DM without interstitial lung disease or malignancy, whereas anti-155/140 was associated with malignancy. Patients with anti-CADM-140 frequently had clinically amyopathic DM and rapidly progressive interstitial lung disease. Cumulative survival rates were more favorable in patients with anti-Mi-2 compared with those with anti-155/140 or anti-CADM-140 (P < .01 for both comparisons). Nearly all deaths occurred within 1 year after diagnosis in patients with anti-CADM-140. Conclusion: Dermatomyositis-specific Abs define clinically distinct subsets and are useful for predicting clinical outcomes in patients with DM.
AB - Objective: To clarify the association of clinical and prognostic features with dermatomyositis (DM)-specific autoantibodies (Abs) in adult Japanese patients with DM. Design: Retrospective study. Setting: Kanazawa University Graduate School of Medical Science Department of Dermatology and collaborating medical centers. Patients: A total of 376 consecutive adult Japanese patients with DM who visited our hospital or collaborating medical centers between 2003 and 2008. Main Outcome Measures: Clinical and laboratory characteristics of adult Japanese patients with DM and DMspecific Abs that include Abs against Mi-2, 155/140, and CADM-140. Results: In patients with DM, anti-Mi-2, anti-155/140, and anti-CADM-140 were detected in 9 (2%), 25 (7%), and 43 (11%), respectively. These DM-specific Abs were mutually exclusive and were detected in none of 34 patients with polymyositis, 326 with systemic sclerosis, and 97 with systemic lupus erythematosus. Anti-Mi-2 was associated with classical DM without interstitial lung disease or malignancy, whereas anti-155/140 was associated with malignancy. Patients with anti-CADM-140 frequently had clinically amyopathic DM and rapidly progressive interstitial lung disease. Cumulative survival rates were more favorable in patients with anti-Mi-2 compared with those with anti-155/140 or anti-CADM-140 (P < .01 for both comparisons). Nearly all deaths occurred within 1 year after diagnosis in patients with anti-CADM-140. Conclusion: Dermatomyositis-specific Abs define clinically distinct subsets and are useful for predicting clinical outcomes in patients with DM.
UR - http://www.scopus.com/inward/record.url?scp=79953837289&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79953837289&partnerID=8YFLogxK
U2 - 10.1001/archdermatol.2011.52
DO - 10.1001/archdermatol.2011.52
M3 - Article
C2 - 21482889
AN - SCOPUS:79953837289
VL - 147
SP - 391
EP - 398
JO - JAMA Dermatology
JF - JAMA Dermatology
SN - 2168-6068
IS - 4
ER -